It's been a challenging year for streaming giant Roku (NASDAQ: ROKU). The company is struggling amid macroeconomic challenges, its financial results have been subpar, and investors have sold off the stock, which is down by a whopping 75% year to date. How will Roku respond to these headwinds in the coming few quarters? Read More...
Motley Fool
Why Shares of Veru Fell 10.33% on Monday
Veru (NASDAQ: VERU), a biopharmaceutical company that looks for novel cancer therapies, particularly in breast cancer or prostate cancer, saw its shares drop 10.33% on Monday. The company’s stock already lost $10 a share two weeks ago when a Food and Drug Administration (FDA) advisory panel voted 8-5 against approving sabizabulin, Veru’s COVID-19 oral therapy, via the Emergency Use Authorization route. It’s not the last word, but the FDA usually agrees with advisory panels’ votes.
